Cargando...

Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks

OBJECTIVE: We recently reported that after 26 weeks, exenatide once weekly (EQW) resulted in superior A1C reduction, reduced hypoglycemia, and progressive weight loss compared with daily insulin glargine (IG) in patients with type 2 diabetes who were taking metformin alone or with sulfonylurea. This...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Diamant, Michaela, Van Gaal, Luc, Stranks, Stephen, Guerci, Bruno, MacConell, Leigh, Haber, Harry, Scism-Bacon, Jamie, Trautmann, Michael
Formato: Artigo
Idioma:Inglês
Publicado: American Diabetes Association 2012
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3308312/
https://ncbi.nlm.nih.gov/pubmed/22357185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc11-1233
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!